Dashboard
Manage Tickers

RVTY REVVITY, INC.

NYSE perkinelmer.com


$ 95.64 $ -1.21 (-1.25 %)    

Wednesday, 22-Oct-2025 15:59:58 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 604.27 $ -5.89 (-0.96 %)
DIA $ 464.98 $ -3.44 (-0.73 %)
SPY $ 666.76 $ -3.49 (-0.52 %)
TLT $ 92.19 $ 0.06 (0.07 %)
GLD $ 376.01 $ 0.04 (0.01 %)
$ 95.68
$ 96.52
$ 95.00 x 27
$ 100.00 x 250
$ 95.54 - $ 98.48
$ 81.30 - $ 129.14
1,315,783
na
11.11B
$ 0.99
$ 38.94
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-05-2025 06-29-2025 10-Q
2 05-06-2025 03-30-2025 10-Q
3 02-25-2025 12-29-2024 10-K
4 11-06-2024 09-29-2024 10-Q
5 08-06-2024 06-30-2024 10-Q
6 05-07-2024 03-31-2024 10-Q
7 02-27-2024 12-31-2023 10-K
8 11-07-2023 10-01-2023 10-Q
9 08-09-2023 07-02-2023 10-Q
10 05-12-2023 04-02-2023 10-Q
11 03-01-2023 01-01-2023 10-K
12 11-14-2022 10-02-2022 10-Q
13 08-09-2022 07-03-2022 10-Q
14 05-10-2022 04-03-2022 10-Q
15 03-03-2022 01-02-2022 10-K
16 11-09-2021 10-03-2021 10-Q
17 08-10-2021 07-04-2021 10-Q
18 05-11-2021 04-04-2021 10-Q
19 03-02-2021 01-03-2021 10-K
20 11-10-2020 10-04-2020 10-Q
21 08-11-2020 07-05-2020 10-Q
22 05-12-2020 04-05-2020 10-Q
23 02-25-2020 12-29-2019 10-K
24 11-05-2019 09-29-2019 10-Q
25 08-06-2019 06-30-2019 10-Q
26 05-07-2019 03-31-2019 10-Q
27 02-26-2019 12-30-2018 10-K
28 11-06-2018 09-30-2018 10-Q
29 08-07-2018 07-01-2018 10-Q
30 05-08-2018 04-01-2018 10-Q
31 02-27-2018 12-31-2017 10-K
32 11-07-2017 10-01-2017 10-Q
33 08-08-2017 07-02-2017 10-Q
34 05-09-2017 04-02-2017 10-Q
35 02-28-2017 01-01-2017 10-K
36 11-08-2016 10-02-2016 10-Q
37 08-09-2016 07-03-2016 10-Q
38 05-10-2016 04-03-2016 10-Q
39 03-01-2016 01-03-2016 10-K
40 11-10-2015 10-04-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

whats-driving-the-market-sentiment-around-revvity-inc
What's Driving the Market Sentiment Around...
10/21/2025 13:00:59

guggenheim-initiates-coverage-on-revvity-with-neutral-rating
Guggenheim Initiates Coverage On Revvity w...
10/16/2025 12:52:29

Guggenheim analyst Subbu Nambi initiates coverage on Revvity (NYSE:RVTY) with a Neutral rating.

evercore-isi-group-maintains-outperform-on-revvity-lowers-price-target-to-106
Evercore ISI Group Maintains Outperform on...
10/07/2025 17:52:41

Evercore ISI Group analyst Vijay Kumar maintains Revvity (NYSE:RVTY) with a Outperform and lowers the price target from $108...

what-analysts-are-saying-about-revvity-stock
What Analysts Are Saying About Revvity Stock
10/02/2025 14:01:25

Core News & Articles
Revvity Expands Type 1 Diabetes Portfolio ...
10/02/2025 12:04:49

Initiative spans an IVD assay and a new Revvity Omics lab-developed test to expand clinical testing for early-stage disease scr...

b-of-a-securities-maintains-buy-on-revvity-lowers-price-target-to-99
B of A Securities Maintains Buy on Revvity...
09/22/2025 18:07:27

B of A Securities analyst Michael Ryskin maintains Revvity (NYSE:RVTY) with a Buy and lowers the price target from $110 to $99.

is-revvity-gaining-or-losing-market-support
Is Revvity Gaining or Losing Market Support?
09/10/2025 17:00:47

alphabet-apple-fuel-tech-rebound-gold-defies-gravity-whats-moving-markets-wednesday
Alphabet, Apple Fuel Tech Rebound, Gold De...
09/03/2025 18:09:52

Wall Street staged a tentative rebound on Wednesday after two straight sessions of heavy tech losses, as rallies in Alphabet Inc.

revvity-unveils-phsense-reagents-to-advance-internalization-studies-in-drug-discovery
Revvity Unveils pHSense Reagents To Advanc...
08/06/2025 12:13:04

Innovative plate-based internalization reagents designed to deliver accurate, high-throughput, and scalable insights for GPCR a...

a-glimpse-into-the-expert-outlook-on-revvity-through-5-analysts
A Glimpse Into The Expert Outlook On Revvi...
07/29/2025 14:01:56

raymond-james-reiterates-outperform-on-revvity-lowers-price-target-to-115
Raymond James Reiterates Outperform on Rev...
07/29/2025 14:01:22

Raymond James analyst Andrew Cooper reiterates Revvity (NYSE:RVTY) with a Outperform and lowers the price target from $120 t...

stifel-maintains-hold-on-revvity-lowers-price-target-to-110
Stifel Maintains Hold on Revvity, Lowers P...
07/29/2025 13:21:35

Stifel analyst Daniel Arias maintains Revvity (NYSE:RVTY) with a Hold and lowers the price target from $120 to $110.

oil-energy-stocks-rise-dollar-rallies-on-us-eu-trade-deal-whats-moving-markets-monday
Oil, Energy Stocks Rise, Dollar Rallies On...
07/28/2025 16:52:04

Wall Street opened the week slightly higher, led by gains in energy stocks, while the U.S. dollar posted its strongest performa...

revvity-slashes-outlook-as-china-policy-deals-diagnostics-blow
Revvity Slashes Outlook As China Policy De...
07/28/2025 15:51:41

Revvity beat Q2 earnings estimates but cut its 2025 profit outlook as China policy changes hit its immunodiagnostics business.

atai-life-sciences-revvity-and-other-big-stocks-moving-lower-in-mondays-pre-market-session
ATAI Life Sciences, Revvity And Other Big ...
07/28/2025 12:13:34

Core News & Articles
12 Health Care Stocks Moving In Monday's P...
07/28/2025 12:08:27

revvity-lowers-fy2025-adj-eps-guidance-from-490-500-to-485-495-vs-493-est-raises-fy2025-sales-guidance-from-2830b-2870b-to-2840b-2880b-vs-2852b-est
Revvity Lowers FY2025 Adj EPS Guidance fro...
07/28/2025 10:02:57

For the full year 2025, the Company is raising its full year revenue guidance to $2.84-$2.88 billion to reflect recent changes ...

revvity-q2-2025-adj-eps-118-beats-114-estimate-sales-720284m-beat-710709m-estimate
Revvity Q2 2025 Adj. EPS $1.18 Beats $1.14...
07/28/2025 10:01:21

Core News & Articles
Earnings Scheduled For July 28, 2025
07/28/2025 08:32:17

a-glimpse-of-revvitys-earnings-potential
A Glimpse of Revvity's Earnings Potential
07/25/2025 14:02:37

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION